July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
Author Affiliations & Notes
  • Peter Cackett
    Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, Scotland, UK, Edinburgh, United Kingdom
    University of Edinburgh, Edinburgh, United Kingdom
  • Flora Elwes
    New Royal Infirmary, Edinburgh, Edinburgh, United Kingdom
  • Peter Aspinall
    Heriot Watt University, Edinburgh, Edinburgh, United Kingdom
    University of Edinburgh, Edinburgh, United Kingdom
  • Peng Yong Sim
    University of Edinburgh, Edinburgh, United Kingdom
  • Cheng Yi Loo
    University of Edinburgh, Edinburgh, United Kingdom
  • Bal Dhillon
    Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, Scotland, UK, Edinburgh, United Kingdom
    University of Edinburgh, Edinburgh, United Kingdom
  • Ana Maria Armbrecht
    Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, Scotland, UK, Edinburgh, United Kingdom
  • Ali Al-Ani
    Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, Scotland, UK, Edinburgh, United Kingdom
  • Shyamanga Borooah
    Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, Scotland, UK, Edinburgh, United Kingdom
    University of Edinburgh, Edinburgh, United Kingdom
  • Footnotes
    Commercial Relationships   Peter Cackett, Bayer (R), Novartis (R); Flora Elwes, Bayer (R); Peter Aspinall, None; Peng Yong Sim, None; Cheng Loo, None; Bal Dhillon, None; Ana Maria Armbrecht, None; Ali Al-Ani, None; Shyamanga Borooah, Bayer (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2383. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter Cackett, Flora Elwes, Peter Aspinall, Peng Yong Sim, Cheng Yi Loo, Bal Dhillon, Ana Maria Armbrecht, Ali Al-Ani, Shyamanga Borooah; Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2383.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We wanted to assess the effect of switching patients previously incompletely treated with ranibizumab (RBZ) to aflibercept (AFL) using a pro re nata (PRN) treatment strategy in neovascular age-related macular degeneration (nvAMD).

Methods : A longitudinal cohort study was conducted on patients who had persistent or recurrent intra- and/or sub-retinal fluid treated initially with RBZ and subsequently switched to AFL. The main outcome measures were best corrected visual acuity (BCVA) and central retinal thickness (CRT) measured at different stages of the study. Friedman analysis of variance and Wilcoxon test were used to examine differences in BCVA and CRT.

Results : 207 eyes from 182 patients with nvAMD were included. BCVA and CRT improved significantly initially following 3 RBZ injections with a mean gain of 3.7 letters (p<0.001) and a mean decrease of 69μm (p<0.001) respectively. Following PRN RBZ therapy and immediately prior to switching to AFL (mean 129 weeks), there was a mean loss of 6.7 letters (p<0.001) BCVA and a mean gain of 24μm (p<0.001) CRT. AFL loading resulted in a mean improvement of 0.7 letters (p=0.28) BCVA and a mean decrease of 55μm (p<0.001) CRT. At final follow-up following AFL PRN therapy (mean 85 weeks), there was a mean loss of 8.9 letters (p<0.001) BCVA and a mean gain of 12μm (p<0.05) CRT.

Conclusions : Following switch of anti-VEGF agent, AFL loading resulted in a significant anatomical improvement but no significant change in visual acuity. However, the benefits of switching were gradually lost over time with AFL PRN dosing despite an increased injection rate. The gradual reduction in vision following switch most likely represents a continued retinal degenerative process which started prior to switch and could not be halted by AFL therapy, tachyphylaxis to anti-VEGF therapy and also the result of the reactive treatment regimen in place at the time of the study.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×